netFormulary Coventry and Warwickshire Area Prescribing Committee NHS
Formulary  
 Search
 Formulary Chapter 8: Malignant disease and immunosuppression - Full Chapter
08.02.04  Expand sub section  Other immunomodulating drugs
Canakinumab
View adult BNF View SPC online View childrens BNF
Formulary
Red SO
Treatment for all licensed indications 
   
Cobimetinib
View adult BNF View SPC online View childrens BNF
Formulary
Red SO
Treatment of unresectable or metastatic melanoma with a BRAF V600 mutation

 
   
Dimethyl fumarate
View adult BNF View SPC online View childrens BNF
Formulary
Red SO
Treatment of relapsing remitting multiple sclerosis
 
Link  NICE TA320: Dimethyl fumarate for treating relapsing‑remitting multiple sclerosis
   
Fampridine
View adult BNF View SPC online View childrens BNF
Formulary
Red SO
Improvement of walking disability in multiple sclerosis
 
   
Fingolimod
View adult BNF View SPC online View childrens BNF
Formulary
Red SO

Treatment of highly active relapsing-remitting multiple sclerosis

 
Link  NICE TA254: Fingolimod for highly active relapsing remitting multiple sclerosis
   
Histamine
View adult BNF View SPC online View childrens BNF
Formulary
Red SO
Treatment of Acute Myeloid Leukaemia in combination with aldesleukin
 
   
Lenalidomide
View adult BNF View SPC online View childrens BNF
Formulary
Red SO
Treatment of myelodysplastic syndrome, multiple myeloma and mantle cell lymphoma
 
Link  NICE TA171: Multiple myeloma - lenalidomide
Link  NICE TA322: Lenalidomide for treating myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality
   
Nivolumab
View adult BNF View SPC online View childrens BNF
Formulary
Red SO
Treatment of melanoma, lung and renal cancer
 
Link  NICE TA384: Nivolumab for treating advanced (unresectable or metastatic) melanoma
Link  NICE TA417: Nivolumab for previously treated advanced renal cell carcinoma
Link  NICE TA462: Nivolumab for treating relapsed or refractory classical Hodgkin lymphoma
Link  NICE TA483: Nivolumab for previously treated squamous non-small-cell lung cancer
Link  NICE TA484: Nivolumab for previously treated non-squamous non-small-cell lung cancer
Link  NICE TA490: Nivolumab for treating squamous cell carcinoma of the head and neck after platinum-based chemotherapy
   
Teriflunomide
View adult BNF View SPC online View childrens BNF
Formulary
Red SO
Treatment of relapsing remitting multiple sclerosis
 
Link  NICE TA303: Teriflunomide for relapsing remitting MS
   
08.02.04  Expand sub section  Interferon Alfa
Interferon Alfa
View adult BNF View SPC online View childrens BNF
Formulary
Amber SC
Treatment of hepatitis B 
   
Interferon Alfa
View adult BNF View SPC online View childrens BNF
Formulary
Red SO
For all licensed indications other than hepatitis B
 
   
Peginterferon alfa (2a & 2b)
View adult BNF View SPC online View childrens BNF
Formulary
Red SO
Treatment of hepatitis B and C
 
Link  NICE TA106: Hepatitis C - peginterferon alfa & ribavirin
Link  NICE TA200: Hepatitis C - peginterferon alfa & ribavirin
Link  NICE TA300: Hepatitis C (children and young people) - peginterferon alfa and ribavirin
Link  NICE TA75: Hepatitis C - pegylated interferons, ribavirin & alfa interferon
   
08.02.04  Expand sub section  Interferon beta
Interferon Beta
View adult BNF View SPC online View childrens BNF
Formulary
Red SO
Treatment of multiple sclerosis
 
   
08.02.04  Expand sub section  Aldesleukin
Aldesleukin (Proleukin®)
View adult BNF View SPC online View childrens BNF
Formulary
Red SO
Treatment of renal cell carcinoma
 
   
BCG bladder instillation
View adult BNF View SPC online View childrens BNF
Formulary
Red SO
Treatment of carcinoma-in-situ of the urinary bladder and prevention of recurrence of superficial papillary transitional cell carcinoma of the urinary bladder after transurethral resection
 
   
Mifamurtide (®)
View adult BNF View SPC online View childrens BNF
Formulary
Red SO
Treatment of osteosarcoma
 
Link  NICE TA154: Hepatitis B - telbivudine
   
08.02.04  Expand sub section  Glatiramer acetate to top
Glatiramer Acetate
View adult BNF View SPC online View childrens BNF
Formulary
Red SO
Treatment of multiple sclerosis
 
   
08.02.04  Expand sub section  Natalizumab
Natalizumab
View adult BNF View SPC online View childrens BNF
Formulary
Red SO
Treatment of highly active relapsing remitting multiple sclerosis
 
Link  NICE TA127: Multiple sclerosis - natalizumab
   
 ....
 Non Formulary Items
Pomalidomide  (Imnovid®)

View adult BNF View SPC online View childrens BNF
Non Formulary
Not Recommended
Relapsed and refractory multiple myeloma in combination with dexamethasone after at least two prior treatment regimens, including both lenalidomide and bortezomib with demonstrated disease progression on the last therapy
Link  NICE TA338: Pomalidomide for relapsed and refractory multiple myeloma previously treated with lenalidomide and bortezomib
 
  
Key
note Notes
Section Title Section Title (top level)
Section Title Section Title (sub level)
First Choice Item First Choice item
Non Formulary Item Non Formulary section
Restricted Drug
Restricted Drug
Unlicensed Drug
Unlicensed
Track Changes
Display tracking information
click to search medicines.org.uk
Link to adult BNF
click to search medicines.org.uk
Link to children's BNF
click to search medicines.org.uk
Link to SPCs
SMC
Scottish Medicines Consortium
Cytotoxic Drug
Cytotoxic Drug
CD
Controlled Drug
High Cost Medicine
High Cost Medicine
Homecare
Homecare

Traffic Light Status Information

Status Description

Preferred

Clinicians are free to prescribe these drugs. They are regarded as cost effective choices which have evidence to support their use.  

Second Line

These drugs should only be prescribed in the scenarios described in the formulary after preferred drug(s) have been ruled out.  

Non Formulary

Non-formulary choice - the vast majority of a patient’s needs should be met by use of formulary preferred choices and second line options when appropriate. Therefore the Clinician should only use a non-formularly drug if this can be justified and it is recommended that all such instances are recorded in the patient record.  

Green SA

Specialist Advised – Specialists may simply advise a patient’s GP to initiate these drugs themselves after they have made an initial assessment. Note: SA drugs can be initiated by the specialist according to patient need and also depending on local commissioning arrangements which may mandate, through the contract between provider and commissioner, that all SA drugs are treated as SI.  

Green SI

Specialist Initiation - These drugs must be initiated, i.e. the first dose prescribed, by the specialist and then may be continued when appropriate by the patient’s GP following communication from the specialist.  

Amber SC

Shared Care - Responsibility for prescribing may be transferred from secondary to primary care with the agreement of an individual GP and when agreed shared care arrangements have been established. The specialist MUST stabilize the patient before asking for care to be transferred. Only specialists should initiate these drugs. Prescribing should be transferred to GPs according to an Shared Care Agreement [SCA]   

Red SO

Specialist Only - These drugs are deemed to be not appropriate for prescribing by GPs. Specialists should not ask GPs to prescribe these drugs.   

Black BL

Black Listed Medicines - These drugs are considered inappropriate for prescribing in Coventry & Warwickshire as they are either not cost-effective or of proven benefit or both.   

Not Recommended

Not Recommended - These are specialist drugs that are not recommended for use.  

netFormulary